spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

Clinical Trial Supply New England

Clinical Trial Supply New England

24-25 March 2020
Boston, US

*Postponed due to the COVID-19 outbreak, new dates to be announced...

Following on from another successful conference Arena International will be returning with full force to Waltham in March to celebrate another edition of the Clinical Trial Supply show. 2020 will gather the key stakeholders in the clinical trials community, including the FDA, US Customs and Border Protection, Biogen, Sanofi, and Blueprint Medicines Corporation. With interactive session formats, fresh content and networking, the event will provide attendees with an unparalleled opportunity for collaboration between players across the whole industry.

web arena-international.com/ctsnewengland
email Boston
 
Print this page
Send to a friend
   
spacer
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>


News and Press Releases

TAGRISSOTM (osimertinib) DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATMENT OF STAGE IB-IIIA COMPLETELY RESECTED PATIENTS WITH EGFR MUTATION

Detailed results from the Phase III ADAURA trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement